Vanguard Global Advisers
LEXX icon

Vanguard Global Advisers’s Lexaria Bioscience LEXX Stock Holding History

Vanguard Global Advisers’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.71K Hold
680
– – ﹤0.01% 3543
2026
Q1 		$7.96K Buy
+680
New +$7.41K ﹤0.01% 3502

Other funds holding LEXX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Global Advisers's LEXX Position: Q2 2026 in Review

Vanguard Global Advisers held its Lexaria Bioscience (LEXX) position steady in Q2 2026 at 680 shares worth $5.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3543.

Vanguard Global Advisers first reported a position in LEXX in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.96K in Q1 2026. 27 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Vanguard Global Advisers held 680 shares of Lexaria Bioscience worth $5.71K as of Q2 2026.
  • Vanguard Global Advisers left its Lexaria Bioscience share count unchanged in Q2 2026.
  • Lexaria Bioscience made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3543 holding.
  • Vanguard Global Advisers first reported a position in Lexaria Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lexaria Bioscience position peaked at $7.96K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.